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Benzodiazepines and Z-drugs may cause prolonged cognitive issues
in young adults e are hypnotics not only a geriatric dilemma?The risks of benzodiazepines (BZDs) in the elderly are well
known. BZD use has been associatedwith increased risks of fallings,
fractures, mobility disabilities, deteriorated activities of daily living,
traffic accidents, chemical restraining and mortality [1e6]. More-
over, acute psychocognitive and motor complications related to
BZDs have been shown in short-term, randomized, controlled trials
[7]. In addition, the newer ‘Z-drugs’ such as zopiclone, zolpidem or
zaleplone have not been shown to be better than conventional
BZDs [8]. Even after adjusting for possible protopathic bias, long-
term BZD use in the elderly has been associated with significantly
higher risk of cognitive decline and dementia compared to non-
users [9].
Currently, the underlying neural mechanisms linking how
BZDS and Z-drugs might cause the long-term cognitive defects
and dementia remain unknown. In a mice experiment [10],
BZDs increased neurotoxic amyloid beta, a key protein involved
in the neuropathology of Alzheimer's disease. Conversely, a hu-
man study [11] could not replicate the finding of increased
neuronal protein accumulations.
Currently, geropharmacologic guidelines do not recommend the
long-term BZD use in the elderly [12,13]. Moreover, practical and
inexpensive interventions can be used to reduce long-term use in
older adults [14e16]. Both notable and worrisome, studies have
shown that in the elderly [17,18] - or in themiddle-aged [19] the ex-
pected cognitive abilities are not recovered after BZD withdrawal.
But are the issues related to BZDs and Z-drugs limited only to
the aged?
Authorities in many countries have accepted short-term use of
short-acting BZDs in appropriate patients. Residual effects of hyp-
notic use on driving abilities have been reported to be conflicting
or related to the half-life of drug used; while hypnotics with
short-half lives have been considered safe, medium- and long-
acting have not [20].
To question the idea of non-existing or low risk of cognitive re-
sidual effects in the young adults, the current issue of Sleep Med-
icine has published a double-blind, randomized controlled trial
“Effects of zolpidem/triazolam on cognitive performance 12 h af-
ter acute administration” by Matsunaga and colleagues [21]. Their
article reports the short-term follow-up results of an experi-
mental trial being a valuable contribution to clinical BZD litera-
ture. Either a placebo or active hypnotic drug (zolpidem or
triazolam) was given to healthy, young male volunteers (mean
age 23.4 ± 3.2 years) in a small cohort (N¼ 13). The authors objec-
tively measured the sleep parameters and the cognitivehttps://doi.org/10.1016/j.sleep.2018.08.011
1389-9457/© 2018 Elsevier B.V. All rights reserved.performance 12 h after administration of hypnotics in three
time-points. The time-interval between individual measures
was at least five days.
The results of Matsunaga and colleagues showed that sleep effi-
ciency was increased after hypnotic drug when compared to pla-
cebo. Cognitive performance measured by a digit symbol
subtraction test was deteriorated even after 12 h after hypnotic
administration, while the psychomotor vigilance test remained un-
changed. Therefore, the authors concluded that cognitive functions
remain deteriorated 12 h after hypnotic drug administration
whereas sleepiness disappears.
The experimental setting is sound, yet includes some flaws.
First, the sample size is small and, thus, their study can be consid-
ered as a well-designed experimental pilot study. Second, there is a
risk of bias as all participants received placebo on the first night and
all threemeasurement points were not completely randomized and
blinded followed by repetitive measuring. However, the authors
had controlled these risks of biases by blinding the participants
and researchers using identical tablets. Moreover, learning effects
in repetitive testing was low as the tests were changed during
the test protocol.
Overall, the findings by Matsunaga and colleagues are disturb-
ing and may reveal a huge risk when employees in high risk occu-
pations have taken hypnotics thought to be safe prior to their
working shifts. According to this trial the risks of errors and acci-
dents are increased because there is still cognitive deterioration
even when not feeling tired.
To increase the external validity, trials on residual cognitive ef-
fects of BZDs and Z-drugs should be replicated in larger young
and middle-aged fully randomized and controlled cohorts. Specif-
ically, practical tests in driving, aviation and nuclear power plant
simulators in addition to other high-risk occupations should be per-
formed in order to find out the clinical meaning of the deteriorated
neuropsychological tests. If the results of future trials are uniform
with the results of the present study by Matsunaga and colleagues,
it is time to re-write the guidelines concerning BZD use in high-risk
occupations.
To understand on the biological level why cognition remains
deteriorated after hypnotic exposure, the neural mechanisms and
neurotoxic changes need to be explored e not only studying cere-
bral protein deposits e but also functionally the neuronal circuits
and brain plasticity before, during and after BZD use.
Finally, benzodiazepines may be a cognitive risk factor e not
only among the elderly e but in young adults as well.
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